CalciMedica, Inc. Files 8-K Report
Ticker: CALC · Form: 8-K · Filed: Dec 20, 2024 · CIK: 1534133
| Field | Detail |
|---|---|
| Company | Calcimedica, INC. (CALC) |
| Form Type | 8-K |
| Filed Date | Dec 20, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $4,450,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, SEC Filing, Corporate Reporting
TL;DR
CalciMedica filed a routine 8-K, nothing major to see here.
AI Summary
On December 20, 2024, CalciMedica, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific material events detailed in the provided text. The company, formerly known as Graybug Vision, Inc., is incorporated in Delaware and headquartered in La Jolla, California.
Why It Matters
This filing indicates routine corporate reporting by CalciMedica, Inc. to the SEC, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — The filing appears to be a standard procedural report without any disclosed material events or changes.
Key Numbers
- 20241220 — Report Date (Date of the 8-K filing)
Key Players & Entities
- CalciMedica, Inc. (company) — Registrant
- Graybug Vision, Inc. (company) — Former company name
- La Jolla, California (location) — Company headquarters
- Delaware (location) — State of incorporation
FAQ
What is the primary purpose of this 8-K filing?
The filing is a Current Report (Form 8-K) pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting on 'Other Events' and 'Financial Statements and Exhibits'.
When was this report filed?
The report was filed on December 20, 2024.
What is CalciMedica, Inc.'s state of incorporation?
CalciMedica, Inc. is incorporated in Delaware.
What is the company's principal executive office address?
The principal executive office is located at 505 Coast Boulevard South, Suite 307, La Jolla, California 92037.
Has CalciMedica, Inc. had previous names?
Yes, the company was formerly known as Graybug Vision, Inc. and Graybug, Inc.
Filing Stats: 553 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-12-20 16:06:00
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share CALC The Nasdaq
- $4,450,000 — an aggregate gross sales price of up to $4,450,000 of shares of Common Stock to be sold pu
Filing Documents
- d882575d8k.htm (8-K) — 26KB
- d882575dex51.htm (EX-5.1) — 10KB
- g882575g1219073508451.jpg (GRAPHIC) — 2KB
- 0001193125-24-283105.txt ( ) — 167KB
- calc-20241220.xsd (EX-101.SCH) — 3KB
- calc-20241220_lab.xml (EX-101.LAB) — 18KB
- calc-20241220_pre.xml (EX-101.PRE) — 11KB
- d882575d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 5.1 Opinion of Cooley LLP 23.1 Consent of Cooley LLP (included in Exhibit 5.1) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. CalciMedica, Inc. Date: December 20, 2024 By: /s/ A. Rachel Leheny A. Rachel Leheny Chief Executive Officer